Work

Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May–June 2020, Pages 322-330.e5

Year: 2020

Type: erratum

Abstract: The authors regret that the “Q2W” in the columns Cohort 3 and 4 in tables 3, 4 and 5 should be “Q4W”. The authors would like to apologise for any inconvenience caused. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS studyJournal of Clinical LipidologyVol. 14Issue 3PreviewHeterozygous familial hypercholesterolemia (HeFH) is a genetic disorder characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C). Full-Text PDF Open Access

Source: Journal of clinical lipidology

DOI: 10.1016/j.jacl.2020.08.011

Authors: Stephen Daniels, Sonia Caprio, Umesh Chaudhari, Garen Manvelian, Marie T. Baccara-Dinet, Aurelie Brunet, Michel Scemama, Virginie Loizeau, Eric Bruckert

Institutions: University of Colorado Anschutz, Yale University, Regeneron (United States), Sanofi (France), Pitié-Salpêtrière Hospital, Fondation pour l’innovation en Cadiométabolisme et Nutrition

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,950

OpenAlex ID: W4241581678

Cites:

Cited by: 1

Related to: 10